All exceeded the 2G-A (CD28) CAR to direct sustained T cell expansion (Figure 7G), tumor-cell killing (Figure 7H), and cytokine release (Figure 7I) over multiple stimulation cycles. This evidence concerns the gene CD28 and neoplasm.